Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-05

AUTHORS

B. J. Lipworth, L. C. McFarlane, W. J. Coutie, D. G. McDevitt

ABSTRACT

The aim of the present study was to evaluate whether metabolic responses to inhaled salbutamol may be used to measure the cardioselectivity of beta-adrenoceptor antagonists. We therefore studied the effects of oral doses of atenolol 50 mg, 100 mg, 200 mg (A50, A100, A200), propranolol 40 mg (P40), and placebo (Pl) on the hypokalaemic (K) and hyperglycaemic (Glu) responses to inhaled salbutamol in five healthy subjects.Increasing doses of atenolol were associated with a progressive attenuation of ΔK compared with placebo: −0.72 mmol·l−1 (Pl) vs −0.20 mmol·l−1 (A200). However, ΔK with A200 was significantly different from the response with P40: +0.12 mmol·l−1. There were partial reductions in the hyperglycaemic response with the beta-adrenoceptor antagonists, although this was only significant (compared with Pl) for P40: ΔGlu 1.92 mmol·l−1 (Pl) vs 0.76 mmol·l−1 (P40).These results show that beta2-adrenoceptor blockade by atenolol is a dose-dependent phenomenon, which may be measured by the attenuation of salbutamol-induced hypokalaemia. However, beta2-adrenoceptor blockade by atenolol 200 mg was less than that by propranolol 40 mg. The glucose response to salbutamol was only partially blocked by propranolol and may therefore not be suitable to assess beta2-adrenoceptor antagonism. More... »

PAGES

297-300

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00679788

DOI

http://dx.doi.org/10.1007/bf00679788

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1012896847

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2575521


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Inhalation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adrenergic beta-Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Albuterol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atenolol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Potassium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Propranolol", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK", 
          "id": "http://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lipworth", 
        "givenName": "B. J.", 
        "id": "sg:person.0733153704.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733153704.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK", 
          "id": "http://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McFarlane", 
        "givenName": "L. C.", 
        "id": "sg:person.01121422652.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121422652.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK", 
          "id": "http://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coutie", 
        "givenName": "W. J.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK", 
          "id": "http://www.grid.ac/institutes/grid.416266.1", 
          "name": [
            "Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McDevitt", 
        "givenName": "D. G.", 
        "id": "sg:person.07372627754.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372627754.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/clpt.1981.59", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007923268", 
          "https://doi.org/10.1038/clpt.1981.59"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00558154", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053402712", 
          "https://doi.org/10.1007/bf00558154"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-05", 
    "datePublishedReg": "1989-05-01", 
    "description": "The aim of the present study was to evaluate whether metabolic responses to inhaled salbutamol may be used to measure the cardioselectivity of beta-adrenoceptor antagonists. We therefore studied the effects of oral doses of atenolol 50 mg, 100 mg, 200 mg (A50, A100, A200), propranolol 40 mg (P40), and placebo (Pl) on the hypokalaemic (K) and hyperglycaemic (Glu) responses to inhaled salbutamol in five healthy subjects.Increasing doses of atenolol were associated with a progressive attenuation of \u0394K compared with placebo: \u22120.72 mmol\u00b7l\u22121 (Pl) vs \u22120.20 mmol\u00b7l\u22121 (A200). However, \u0394K with A200 was significantly different from the response with P40: +0.12 mmol\u00b7l\u22121. There were partial reductions in the hyperglycaemic response with the beta-adrenoceptor antagonists, although this was only significant (compared with Pl) for P40: \u0394Glu 1.92 mmol\u00b7l\u22121 (Pl) vs 0.76 mmol\u00b7l\u22121 (P40).These results show that beta2-adrenoceptor blockade by atenolol is a dose-dependent phenomenon, which may be measured by the attenuation of salbutamol-induced hypokalaemia. However, beta2-adrenoceptor blockade by atenolol 200 mg was less than that by propranolol 40 mg. The glucose response to salbutamol was only partially blocked by propranolol and may therefore not be suitable to assess beta2-adrenoceptor antagonism.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00679788", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "beta2-adrenoceptor blockade", 
      "beta-adrenoceptor antagonists", 
      "doses of atenolol", 
      "metabolic response", 
      "dose-dependent phenomenon", 
      "oral doses", 
      "hyperglycaemic response", 
      "healthy subjects", 
      "glucose response", 
      "salbutamol", 
      "blockade", 
      "atenolol", 
      "progressive attenuation", 
      "placebo", 
      "propranolol", 
      "antagonist", 
      "doses", 
      "present study", 
      "p40", 
      "response", 
      "hypokalaemia", 
      "cardioselectivity", 
      "hypokalaemic", 
      "antagonism", 
      "subjects", 
      "aim", 
      "attenuation", 
      "vs", 
      "partial reduction", 
      "evaluation", 
      "study", 
      "reduction", 
      "effect", 
      "results", 
      "A200", 
      "measurements", 
      "phenomenon", 
      "\u0394K"
    ], 
    "name": "Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade", 
    "pagination": "297-300", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1012896847"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00679788"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2575521"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00679788", 
      "https://app.dimensions.ai/details/publication/pub.1012896847"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_182.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00679788"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00679788'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00679788'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00679788'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00679788'


 

This table displays all metadata directly associated to this object as RDF triples.

167 TRIPLES      21 PREDICATES      76 URIs      66 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00679788 schema:about N05de63368c8c415f872448714142294b
2 N0b7e8f86825f41388d65fc48058109ac
3 N183c393ea7e6487bae5da275d89ceec3
4 N20c93090205b4daea8c2ba391353f315
5 N3df8f3c5534b4a32b56fb32ca92b76de
6 N611b0d454bc44a9eb468cabca7a2edde
7 N67fc7af4048146a78b4932894cbfe431
8 N6a65254defc54687a778e2a78d54f3eb
9 Nd2b8ddbf52ff45299d3ddfc918d8e08e
10 Nff2342872e9d49c7b6281186d3779333
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author Nfb56a6ddedfd4ce59ef0cef1e6836cfa
14 schema:citation sg:pub.10.1007/bf00558154
15 sg:pub.10.1038/clpt.1981.59
16 schema:datePublished 1989-05
17 schema:datePublishedReg 1989-05-01
18 schema:description The aim of the present study was to evaluate whether metabolic responses to inhaled salbutamol may be used to measure the cardioselectivity of beta-adrenoceptor antagonists. We therefore studied the effects of oral doses of atenolol 50 mg, 100 mg, 200 mg (A50, A100, A200), propranolol 40 mg (P40), and placebo (Pl) on the hypokalaemic (K) and hyperglycaemic (Glu) responses to inhaled salbutamol in five healthy subjects.Increasing doses of atenolol were associated with a progressive attenuation of ΔK compared with placebo: −0.72 mmol·l−1 (Pl) vs −0.20 mmol·l−1 (A200). However, ΔK with A200 was significantly different from the response with P40: +0.12 mmol·l−1. There were partial reductions in the hyperglycaemic response with the beta-adrenoceptor antagonists, although this was only significant (compared with Pl) for P40: ΔGlu 1.92 mmol·l−1 (Pl) vs 0.76 mmol·l−1 (P40).These results show that beta2-adrenoceptor blockade by atenolol is a dose-dependent phenomenon, which may be measured by the attenuation of salbutamol-induced hypokalaemia. However, beta2-adrenoceptor blockade by atenolol 200 mg was less than that by propranolol 40 mg. The glucose response to salbutamol was only partially blocked by propranolol and may therefore not be suitable to assess beta2-adrenoceptor antagonism.
19 schema:genre article
20 schema:isAccessibleForFree false
21 schema:isPartOf N1ad0182a698b4a6280b0102f3f6e32cd
22 Ne6274fbbefe148ef98f3876998e00d48
23 sg:journal.1054337
24 schema:keywords A200
25 aim
26 antagonism
27 antagonist
28 atenolol
29 attenuation
30 beta-adrenoceptor antagonists
31 beta2-adrenoceptor blockade
32 blockade
33 cardioselectivity
34 dose-dependent phenomenon
35 doses
36 doses of atenolol
37 effect
38 evaluation
39 glucose response
40 healthy subjects
41 hyperglycaemic response
42 hypokalaemia
43 hypokalaemic
44 measurements
45 metabolic response
46 oral doses
47 p40
48 partial reduction
49 phenomenon
50 placebo
51 present study
52 progressive attenuation
53 propranolol
54 reduction
55 response
56 results
57 salbutamol
58 study
59 subjects
60 vs
61 ΔK
62 schema:name Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta2-adrenoceptor blockade
63 schema:pagination 297-300
64 schema:productId N23764f0f30d340ed869a6c8f56d01bd5
65 N95d142bd108343df870a34def15da11e
66 Nc9cfc89a43a04679ae1468edb54179f2
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012896847
68 https://doi.org/10.1007/bf00679788
69 schema:sdDatePublished 2022-11-24T20:46
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher Nc2e7ef4dfc8d4d5384a6351ddfe2593c
72 schema:url https://doi.org/10.1007/bf00679788
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N05de63368c8c415f872448714142294b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Propranolol
78 rdf:type schema:DefinedTerm
79 N063badce268a4e3399318a8f95b42b9c rdf:first N633f4e85678146669c818cc80b19e3a0
80 rdf:rest N9f007b6712de42deab7f35caf0a0a7cf
81 N0b7e8f86825f41388d65fc48058109ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Administration, Inhalation
83 rdf:type schema:DefinedTerm
84 N183c393ea7e6487bae5da275d89ceec3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Male
86 rdf:type schema:DefinedTerm
87 N1ad0182a698b4a6280b0102f3f6e32cd schema:issueNumber 3
88 rdf:type schema:PublicationIssue
89 N20c93090205b4daea8c2ba391353f315 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Atenolol
91 rdf:type schema:DefinedTerm
92 N23764f0f30d340ed869a6c8f56d01bd5 schema:name doi
93 schema:value 10.1007/bf00679788
94 rdf:type schema:PropertyValue
95 N3df8f3c5534b4a32b56fb32ca92b76de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Adult
97 rdf:type schema:DefinedTerm
98 N5e94b2cb804045488397d594e43de8ea rdf:first sg:person.01121422652.39
99 rdf:rest N063badce268a4e3399318a8f95b42b9c
100 N611b0d454bc44a9eb468cabca7a2edde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Potassium
102 rdf:type schema:DefinedTerm
103 N633f4e85678146669c818cc80b19e3a0 schema:affiliation grid-institutes:grid.416266.1
104 schema:familyName Coutie
105 schema:givenName W. J.
106 rdf:type schema:Person
107 N67fc7af4048146a78b4932894cbfe431 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Albuterol
109 rdf:type schema:DefinedTerm
110 N6a65254defc54687a778e2a78d54f3eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Humans
112 rdf:type schema:DefinedTerm
113 N95d142bd108343df870a34def15da11e schema:name dimensions_id
114 schema:value pub.1012896847
115 rdf:type schema:PropertyValue
116 N9f007b6712de42deab7f35caf0a0a7cf rdf:first sg:person.07372627754.48
117 rdf:rest rdf:nil
118 Nc2e7ef4dfc8d4d5384a6351ddfe2593c schema:name Springer Nature - SN SciGraph project
119 rdf:type schema:Organization
120 Nc9cfc89a43a04679ae1468edb54179f2 schema:name pubmed_id
121 schema:value 2575521
122 rdf:type schema:PropertyValue
123 Nd2b8ddbf52ff45299d3ddfc918d8e08e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Adrenergic beta-Antagonists
125 rdf:type schema:DefinedTerm
126 Ne6274fbbefe148ef98f3876998e00d48 schema:volumeNumber 37
127 rdf:type schema:PublicationVolume
128 Nfb56a6ddedfd4ce59ef0cef1e6836cfa rdf:first sg:person.0733153704.36
129 rdf:rest N5e94b2cb804045488397d594e43de8ea
130 Nff2342872e9d49c7b6281186d3779333 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Blood Glucose
132 rdf:type schema:DefinedTerm
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
137 schema:name Clinical Sciences
138 rdf:type schema:DefinedTerm
139 sg:journal.1054337 schema:issn 0031-6970
140 1432-1041
141 schema:name European Journal of Clinical Pharmacology
142 schema:publisher Springer Nature
143 rdf:type schema:Periodical
144 sg:person.01121422652.39 schema:affiliation grid-institutes:grid.416266.1
145 schema:familyName McFarlane
146 schema:givenName L. C.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121422652.39
148 rdf:type schema:Person
149 sg:person.0733153704.36 schema:affiliation grid-institutes:grid.416266.1
150 schema:familyName Lipworth
151 schema:givenName B. J.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733153704.36
153 rdf:type schema:Person
154 sg:person.07372627754.48 schema:affiliation grid-institutes:grid.416266.1
155 schema:familyName McDevitt
156 schema:givenName D. G.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372627754.48
158 rdf:type schema:Person
159 sg:pub.10.1007/bf00558154 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053402712
160 https://doi.org/10.1007/bf00558154
161 rdf:type schema:CreativeWork
162 sg:pub.10.1038/clpt.1981.59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007923268
163 https://doi.org/10.1038/clpt.1981.59
164 rdf:type schema:CreativeWork
165 grid-institutes:grid.416266.1 schema:alternateName Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK
166 schema:name Department of Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, Scotland, UK
167 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...